Literature DB >> 28289872

Criteria sets for primary Sjogren's syndrome are not adequate for those presenting with extraglandular organ involvements as their dominant clinical features.

Yasemin Kabasakal1, Gul Kitapçıoğlu2, Gonca Karabulut3, Mehmet Tezcan4, Ayse Balkarlı5, Adem Aksoy6, Şule Yavuz7, Sema Yılmaz8, Timuçin Kaşifoğlu9, Umut Kalyoncu10, Ediz Dalkılıç11, Abdurrahman Tufan4, Rıdvan Mercan4, Fatih Yıldız12, Taşkın Şentürk13, Fatoş Önen6, Cemal Bes14, Eren Erken12, Ercan Tunç15, Sevil Kamalı16, Emine Tarhan17, Ayten Yazıcı18, Nurşen Düzgün19, Müge Bıçakçıgil20, Sedat Yılmaz21, Mustafa Özmen22, Lale Öcal16, Fatma Alibaz-Öner7, Dilek Solmaz6, Veli Çobankara5, Selim Nalbant23, Esen Kasapoğlu Günal24, Derya Kaşkari25, Berna Göker4.   

Abstract

Patients with primary Sjogren's syndrome (pSS) may go undiagnosed or be misclassified due to the insidious nature and wide spectrum of the disease. The available several classification criteria emphasize glandular findings. We aimed to analyze the efficiency of various classification criteria sets in patients diagnosed on the clinical basis by expert opinion and to compare those pSS patients who fulfilled these criteria with those who did not. This is a multicenter study in which 834 patients from 22 university-based rheumatology clinics are included. Diagnosis of pSS was made on the clinical basis by the expert opinion. In this study, we only interviewed patients once and collected available data from the medical records. The European criteria, American-European Consensus Group (AECG) and American College of Rheumatology (ACR) Sjogren's criteria were applied. Majority of the patients were women (F/M was 20/1). The median duration from the first pSS-related symptom to diagnosis was significantly shorter in men (2.5 ± 2.3 vs 4.3 ± 5.9 years) (p = 0 < 0.016). When the European, AECG and ACR Sjogren's criteria were applied, 666 patients (79.9%) satisfied at least one of them. In total, 539 patients (64.4%) satisfied the European, 439 (52.6%) satisfied the AECG, and 359 (43%) satisfied the ACR criteria. Among the entire group, 250 patients (29.9%) satisfied all and 168 (20.1%) met none of the criteria. The rates of extraglandular organ involvements were not different between patients who met at least one of the criteria sets and those who met none. There is an urgent need for the modification of the pSS criteria sets to prevent exclusion of patients with extraglandular involvements as the dominant clinical features.

Entities:  

Keywords:  Classification criteria; Epidemiology; Extraglandular involvement; Sjogren’s syndrome

Mesh:

Year:  2017        PMID: 28289872     DOI: 10.1007/s00296-017-3691-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.

Authors:  S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

3.  Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.

Authors:  C Vitali; S Bombardieri; H M Moutsopoulos; G Balestrieri; W Bencivelli; R M Bernstein; K B Bjerrum; S Braga; J Coll; S de Vita
Journal:  Arthritis Rheum       Date:  1993-03

4.  Sjögren's syndrome in an out-patient clinic: classification of patients according to the preliminary European criteria and the proposed modified European criteria.

Authors:  J G Brun; T M Madland; C B Gjesdal; L-T Bertelsen
Journal:  Rheumatology (Oxford)       Date:  2002-03       Impact factor: 7.580

5.  Comparison of the American-European Consensus Group Sjogren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort.

Authors:  Astrid Rasmussen; John A Ice; He Li; Kiely Grundahl; Jennifer A Kelly; Lida Radfar; Donald U Stone; Kimberly S Hefner; Juan-Manuel Anaya; Michael Rohrer; Rajaram Gopalakrishnan; Glen D Houston; David M Lewis; James Chodosh; John B Harley; Pamela Hughes; Jacen S Maier-Moore; Courtney G Montgomery; Nelson L Rhodus; A Darise Farris; Barbara M Segal; Roland Jonsson; Christopher J Lessard; R Hal Scofield; Kathy L Moser Sivils
Journal:  Ann Rheum Dis       Date:  2013-08-22       Impact factor: 19.103

6.  Follow-up of primary Sjogren's syndrome patients presenting positive anti-cyclic citrullinated peptides antibody.

Authors:  Yang-Seon Ryu; Sung-Hwan Park; Jennifer Lee; Seung-Ki Kwok; Ji-Hyeon Ju; Ho-Youn Kim; Chan-Hong Jeon
Journal:  Rheumatol Int       Date:  2012-11-21       Impact factor: 2.631

7.  2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts.

Authors:  Caroline H Shiboski; Stephen C Shiboski; Raphaèle Seror; Lindsey A Criswell; Marc Labetoulle; Thomas M Lietman; Astrid Rasmussen; Hal Scofield; Claudio Vitali; Simon J Bowman; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2016-10-26       Impact factor: 19.103

8.  A follow-up study of minimally invasive lip biopsy in the diagnosis of Sjögren's syndrome.

Authors:  Heikki Teppo; Matti Revonta
Journal:  Clin Rheumatol       Date:  2006-11-25       Impact factor: 3.650

9.  Level of agreement between 2002 American-European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren's syndrome and reasons for discrepancies.

Authors:  Divi Cornec; Alain Saraux; Béatrice Cochener; Jacques-Olivier Pers; Sandrine Jousse-Joulin; Yves Renaudineau; Thierry Marhadour; Valérie Devauchelle-Pensec
Journal:  Arthritis Res Ther       Date:  2014-03-19       Impact factor: 5.156

10.  The association between serological biomarkers and primary Sjogren's syndrome associated with peripheral polyneuropathy.

Authors:  Che-Wei Hsu; Yu-Jih Su; Wen-Neng Chang; Nai-Wen Tsai; Wen-Chan Chiu; Ben-Chung Cheng; Chih-Min Su; Chi-Ren Huang; Ya-Ting Chang; Cheng-Hsien Lu
Journal:  Biomed Res Int       Date:  2014-04-13       Impact factor: 3.411

View more
  4 in total

1.  Survival analysis of patients with Sjögren's syndrome in Turkey: a tertiary hospital-based study.

Authors:  Veli Yazisiz; Mesut Göçer; Funda Erbasan; İsmail Uçar; Bengisu Aslan; Şuayp Oygen; Edip Gökalp Gök; Mustafa Ender Terzioğlu
Journal:  Clin Rheumatol       Date:  2019-09-25       Impact factor: 2.980

Review 2.  Cutaneous and Mucosal Manifestations of Sjögren's Syndrome.

Authors:  Elena Generali; Antonio Costanzo; Carlo Mainetti; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

3.  Extended high-frequency audiometry as early detection of hearing loss in primary Sjögren syndrome.

Authors:  José Luis Treviño González; Janett Riega Torres; Yolisa Hinojosa Ríos; Mario Jesús Villegas González; Marco A Mendez Saenz; German A Soto-Galindo
Journal:  Clin Rheumatol       Date:  2017-07-26       Impact factor: 2.980

4.  Olfactory dysfunction in primary Sjogren's syndrome and its correlation with dry eye.

Authors:  Yunus E Topan; Banu Bozkurt; Sema Yılmaz; Çağdaş Elsürer; Sona Gorcuyeva; Mete K Bozkurt
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-10       Impact factor: 2.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.